Müller M J, Lautz H U, Plogmann B, Bürger M, Körber J, Schmidt F W
Medizinische Hochschule Hannover, Department Innere Medizin, Germany.
Hepatology. 1992 May;15(5):782-94. doi: 10.1002/hep.1840150507.
Many clinicians subjectively feel that cirrhotic patients frequently have clinical signs of hypermetabolism. However, it is unknown whether hypermetabolism is a constant feature of chronic liver disease, corresponds to liver destruction and repair or is of prognostic value. This article is about resting energy expenditure and substrate oxidation rates in 123 patients with biopsy-proven cirrhosis differing with respect to cause, duration of the disease, biochemical parameters of parenchymal cell damage, cholestasis, liver function, number of complications, clinical staging and nutritional state. Resting energy expenditure varied between 1,090 and 2,300 kcal/day and differed from the predicted values in 70% of the patients. Resting energy expenditure was closely related to fat-free mass, and 52% of the variability could be explained by fat-free mass, age and sex. Of all the patients, 18% were hypermetabolic and 31% were hypometabolic. Hypermetabolism showed no strict association with the cause of cirrhosis, the duration of the disease, liver function, cholestasis, cell damage, clinical staging, blood hemoglobin, plasma thyroid hormone levels or human leukocyte antigens. An increased resting energy expenditure was associated with significant losses of muscle, body cell mass and extracellular mass at unchanged body fat, whereas fat and fat-free mass were increased in hypometabolic patients when compared with normometabolic patients. Lipid oxidation was increased, but glucose oxidation was reduced in nearly all patients with cirrhosis. This was most pronounced at advanced stages of liver disease. Although similar with respect to liver function and clinical staging, 76.2% of hypermetabolic patients had transplants within the observation period, compared with only 16.7% and 8.1% in the normometabolic group and hypometabolic group, respectively. Posttransplantation mortality was independent of pretransplantation resting energy expenditure, but it increased significantly in patients with losses in body cell mass. In conclusion, hypermetabolism is not a constant feature of cirrhosis and results more from extrahepatic than from hepatic factors. It may cause malnutrition and contributes to the clinical outcome of patients with chronic liver disease.
许多临床医生主观上认为肝硬化患者常有高代谢的临床体征。然而,高代谢是否为慢性肝病的一个持续特征、是否与肝脏破坏及修复相关或是否具有预后价值尚不清楚。本文研究了123例经活检证实为肝硬化患者的静息能量消耗及底物氧化率,这些患者在病因、病程、实质细胞损伤的生化参数、胆汁淤积、肝功能、并发症数量、临床分期及营养状况等方面存在差异。静息能量消耗在1090至2300千卡/天之间,70%的患者与预测值不同。静息能量消耗与去脂体重密切相关,52%的变异性可由去脂体重、年龄和性别解释。所有患者中,18%为高代谢,31%为低代谢。高代谢与肝硬化病因、病程、肝功能、胆汁淤积、细胞损伤、临床分期、血血红蛋白、血浆甲状腺激素水平或人类白细胞抗原无严格关联。静息能量消耗增加与身体脂肪不变时肌肉、体细胞质量和细胞外质量的显著丢失相关,而与正常代谢患者相比,低代谢患者的脂肪和去脂体重增加。几乎所有肝硬化患者的脂质氧化增加,但葡萄糖氧化减少。这在肝病晚期最为明显。尽管在肝功能和临床分期方面相似,但76.2%的高代谢患者在观察期内接受了移植,而正常代谢组和低代谢组分别仅为16.7%和8.1%。移植后死亡率与移植前静息能量消耗无关,但在体细胞质量减少的患者中显著增加。总之,高代谢不是肝硬化的一个持续特征,更多是由肝外而非肝脏因素导致。它可能导致营养不良,并影响慢性肝病患者的临床结局。